Nesiritide for the treatment of congestive heart failure

Bibliography

• JESSUP M, BROZENA S: Heart Failure. N Engl. J. Med. (2003) 348:2007–2018.
   PubMed Web of Science ®Google Scholar
• 2001 Heart and Stroke statistical update. Dallas: American Heart Association (2000).
   Google Scholar
• MCALISTER FA, LAWSON FM, TEO KK, ARMSTRONG PW: A systematic review of randomized trials of disease management programs in heart failure. Am.! Med. (2001) 110:378–384.
   PubMed Web of Science ®Google Scholar
• KONSTAM MA: Progress in heart failure management? Lessons from the real world. Circulation (2000) 102:1076–1078.
   PubMed Web of Science ®Google Scholar
• KHAND A, GEMMEL I, CLARK AL, CLELAND JG: Is the prognosis of heart failure improving? .1. Am. Coll. Cardiol(2000) 36:2284–2286.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, PFEFFER MA: New therapeutic options in congestive heart failure. Circulation (2002) 105:2099-2106; 2223–2228.
   Google Scholar
• MANN D: Mechanisms and models in heart failure: a combinatorial approach.Circulation (1999) 100:999–1008.
   PubMed Web of Science ®Google Scholar
• PACKER M: The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol (1992) 20:248–254.
   PubMed Web of Science ®Google Scholar
• FLORA JS: Clinical aspects of sympatheticactivation and parasympathetic withdrawal in heart failure. Am. Coll. Cardiol (1993) 22(4 Suppl. A):72A–84A.
   Google Scholar
• BENEDICT CR, JOHNSTONE DE, WEINER DH et al.: Relation of neurohormonal activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J. Am. Coll. Cardiol (1994) 23:1410–1420.
   PubMed Web of Science ®Google Scholar
• YASUE H, YOSHIMURA M, SUMIDA H et al.: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of a A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation (1994) 90:1195–1203.
   Google Scholar
• DEBOLD AJ: Atrial natriuretic factor: a hormone produced by the heart. Science(1985) 230(4727):767–770.
   PubMedGoogle Scholar
• TSUTAMOTO T, WADA A, MAEDA K et al.: Plasma brain natriuretic peptide as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1.Eur. Heart J. (1999) 20:1799–1807.
   Google Scholar
• DAO Q, KRISHNASWAMY P, KASANEGRA R et al.: Usefulness of a rapid, bedside test for brain natriureticpeptide in the evaluation of patients presenting to the emergency room with possible congestive heart failure. J. Am. Coll. Cardiol (2000) 35(171A):1049–1052.
   Google Scholar
• YOSHIMURA M, YASUE H, MORITA E et al.: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation (1991) 84:1581–1588.
   PubMed Web of Science ®Google Scholar
• NAKAMURA M, ARAKAWA N, YOSHIDA H et al.: Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135:414–420.
   PubMed Web of Science ®Google Scholar
• HOBBS RE, MILLER LW, BOTT-SILVERMAN C et al: Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol (1996) 78:896–901.
   PubMed Web of Science ®Google Scholar
• MARCUS LS, HART D, PACKER M et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized cross-over trial.Circulation (1996) 94:3184–3189.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.' Card. Fail. (1998) 4:37–44.
   PubMedGoogle Scholar
• MILLS RM, LEJEMTEL TH, HORTON DP et al. On behalf of the Natrecor Study Group: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. .1 Am. Coll. Cardiol (1999) 34:155–162.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, JOHNSON AD, WAGONER L et al.: Nesiritide(human B-type natriuretic peptide) improves symptoms and hemodynamics in NYHA Class III and IV heart failure. J. Am. Coll. Cardiol (1999) 33:188A.
   Google Scholar
• BOURGE RC, ABRAHAM WT, WAGONER LE et al: Nesiritide improves hemodynamics in patients with acutelydecompensated heart failure. J. Card. Fail. (1998) 4:36.
   Google Scholar
• LEJEMTEL TH, BOURGE RC, JOHNSON AD et al: Recombinant human B-type natriuretic peptide improves symptoms and hemodynamics in patients with acutely decompensated CHFAm. Coll. Cardiol (1998) 31:83A.
   PubMedGoogle Scholar
• COLUCCI WS, ELKAYAM U, HORTON DP et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl. J. Med. (2000) 343:246–253.
   PubMed Web of Science ®Google Scholar
• PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure. "AMA (2002) 287:1531–1540.
   Google Scholar
• SILVER MA, HORTON DP, GHALI JK et al.: Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol (2002) 39(5)798–803.
   Google Scholar
• BURGER AJ, HORTON DP,LEJEMTEL T et al.: The effect of Nesiritide (B-type natriuretic peptide and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT Study. Am. Heart J. (2002) 144(6):1102–1108.
   Google Scholar
• SUDOH T, KANGAWA K, MINAMMINO H: A new natriuretic peptide in porcine brain. Nature (1998) 332(6159):78–81.
   Google Scholar
• MUKOYAMA M, NAKAO K, HOSODA K et al.: Brain natriuretic peptide as a novel cardiac hormone in humans." Clin. Invest. (1991) 87:1402–1412.
   Google Scholar
• YASUE H, YOSHIMURA M, SUMIDA H et al.: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type matriuretic peptide in normal subjects and patients with heart failure.Circulation (1994) 90(1):195–203.
   PubMed Web of Science ®Google Scholar
• GOMES MPV, HOBBS RE: B-type (brain)natriuretic peptide: a new therapeutic agent for the treatment of heart failureCongest. Heart Fail. (1998) 4(3):15–21.
   Google Scholar
• ARJONA AA, HSU CA, WRENN DS, HILL NS: Effects of natriuretic peptides on vascular smooth-muscle cells derived fromdifferent vascular beds. Gen. Pharmacol(1997) 28:387–392.
   PubMedGoogle Scholar
• PROTTER AA, WALLACE AM, FERRARIS VA et al.: Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am. J. Hypertens. (1996) 9(5):432–436.
   PubMedGoogle Scholar
• SUGA S-I, NAKAO K, HOSODA K et al: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide. Endocrinology (1992) 130(1):229–239.
   PubMedGoogle Scholar
• LEVIN ER, GARDNER DG, SAMSON WK: Natriuretic peptides. N Engl. J. Med. (1998) 339:321–328.
   PubMed Web of Science ®Google Scholar
• HUNT PJ, ESPINER EA,NICHOLLS MG et al: Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. j Clin. Endocrinol Metal,. (1996) 81(11):3871–3876.
   PubMedGoogle Scholar
• CODY RJ, ATLAS SA, LARAGH JH et al.: Atrial natriuretic factor in normal subjects and heart failure patients. j Clin. Invest. (1986) 78:1362–1374.
   PubMed Web of Science ®Google Scholar
• RODEN RL, ASANO K, WICHMAN S et al.: Inotropic effect of human B-type natriuretic peptide in the failing human heart. J. Card. Fail. (1998) 4(3 Suppl.):8 (Abstract 008).
   Google Scholar
• VILLEREAL D, FREEMAN RH, REAM G: Natriuretic peptides and salt sensitivity: Endocrine cardiorenal integration in heart failure.Congest. Heart Fail. (2002) 8:29–36.
   PubMedGoogle Scholar
• KIRSTEN R, NELSON K, KIRSTEN D, HEINTZ B: Clinical pharmacolkinetics of vasodilators. Part II. Clin. Pharmacokinet. (1998) 35(1):9–36.
   PubMed Web of Science ®Google Scholar
• HOBBS RE, MILLS RM: Therapeutic potential of nesiritide (recombinant B-type natriuretic peptide) in the treatment of heart failure. Expert Opin. Investig. Drugs (1999) 8(7):1063–1072.
   PubMedGoogle Scholar
• ESPINER EA: Physiology of natriuretic peptides. J. Intern. Med. (1994) 235:527–541.
   PubMedGoogle Scholar
• CHARLES CJ, ESPINER EA,NICHOLLS MG et al: Clearance receptors and endopeptidase 24.11: Equal role in natriuretic peptide metabolism in sheep. Am. j Physiol (1996) 271:R373–380.
   Google Scholar
• NORMAN JA, LITTLE D, BOLGAR M et al.: degradation of brain natriuretic peptide by neutral endopeptidase: speciesspecific sites of proteolysis determined by mass spectrometry. Biochem. Biophys. Res. Commun. (1991) 175(1):22–30.
   PubMedGoogle Scholar
• ALMIREZ R, PROTTER AA: Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. Pharmacol Exp. Then (1999) 289(2)976–980.
   Google Scholar
• COLUCCI WS: Nesiritide for the treatment of decompensated heart failure.J. Card. Fail. (2001) 7:92–100.
   PubMedGoogle Scholar
• ELKAYAM U, SILVER MA, BURGER AJ, HORTON DP: The effect of short-term nesiritide therapy with nesiritide (B-type natriuretic peptide) or dobutamine on long term survival. Card. Fail. (2000) 6\(Suppl. 2):45 (Abstract 169).
   Google Scholar
• EMERMAN CL, PEACOCK WE SILVER MA, on behalf of the PROACTION Study Group: Nesiritide added to standard care results in favorable reductions in systolic blood pressure andheart rate compared to standard care alone. Proceedings of the 7-h Annual Scientific Meeting of the Heart Failure Society of America. Las Vegas, USA (2003)(Abstract 221).
   Google Scholar
• YANCY CW, SALTZBERG M, BERKOWITZ RL et al.: Management of patients with congestive heart failure after hospitalization: results from the Follow Up Serial Infusions of Nesiritide (FUSION) Trial. Proceedings of the 7h Annual Scientific Meeting of the Heart Failure Society of America. Las Vegas, USA (2003)(Abstract 34).
   Google Scholar
• http://www.sciosinc.com/scios/natrecor/flash? Scios, Inc.: Natrecor® (nesiritide) for injection.
   Google Scholar